Huang Guichuan, Zhang Jing, Wang Xin, Chen Yi, Liu Daishun, Guo Shuliang
Department of Respiratory and Critical Care Medicine, The First People's Hospital of Zunyi, The Third Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China.
Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, People's Republic of China.
Onco Targets Ther. 2019 May 13;12:3609-3617. doi: 10.2147/OTT.S202081. eCollection 2019.
Nanog has been found to be overexpressed in various cancers. However, the association between Nanog expression and prognosis or clinicopathological features is still controversial. Therefore, this meta-analysis was conducted to identify whether Nanog expression was associated with prognosis or clinicopathological characteristics in non-small cell lung cancer (NSCLC). We searched Embase, PubMed, Web of Science, the Cochrane Library, the Chinese National Knowledge Infrastructure database (CNKI), and the Wanfang database for articles. Pooled hazard ratios (HR), odds ratios (OR), and corresponding 95% confidence intervals (CI) were utilized to evaluate the relationship between Nanog expression and prognosis or clinicopathological characteristics in NSCLC. The results showed that high expression of Nanog was significantly associated with poor overall survival (OS) (HR=1.95, 95% CI: 1.38-2.75, =0.000). Additionally, high Nanog expression was significantly correlated with tumor differentiation (OR=3.18, 95% CI: 1.69-5.98, =0.000) and TNM stage (OR=1.78, 95% CI: 1.28-2.47, =0.001). However, no significant relationship was observed between Nanog expression and other clinicopathological features, including gender (OR=0.95, 95% CI: 0.69-1.33, =0.783), age (OR=0.78, 95% CI: 0.57-1.07, =0.119), tumor size (OR=0.87, 95% CI: 0.26-2.95, =0.824), and lymph node metastasis (OR=1.29, 95% CI: 0.94-1.77, =0.121). High Nanog expression was associated with poor prognosis in patients with NSCLC, and Nanog may serve as a prognostic predictor in NSCLC.
已发现Nanog在多种癌症中过表达。然而，Nanog表达与预后或临床病理特征之间的关联仍存在争议。因此，进行了这项荟萃分析，以确定Nanog表达是否与非小细胞肺癌（NSCLC）的预后或临床病理特征相关。我们在Embase、PubMed、Web of Science、Cochrane图书馆、中国国家知识基础设施数据库（CNKI）和万方数据库中检索文章。采用合并风险比（HR）、比值比（OR）及相应的95%置信区间（CI）来评估Nanog表达与NSCLC预后或临床病理特征之间的关系。结果显示，Nanog高表达与总生存期（OS）差显著相关（HR=1.95，95%CI：1.38 - 2.75，P=0.000）。此外，Nanog高表达与肿瘤分化（OR=3.18，95%CI：1.69 - 5.98，P=0.000）和TNM分期（OR=1.78，95%CI：1.28 - 2.47，P=0.001）显著相关。然而，未观察到Nanog表达与其他临床病理特征之间存在显著关系，包括性别（OR=0.95，95%CI：0.69 - 1.33，P=0.783）、年龄（OR=0.78，95%CI：0.57 - 1.07，P=0.119）、肿瘤大小（OR=0.87，95%CI：0.26 - 2.9 , P=0.824）和淋巴结转移（OR=1.29，95%CI：0.94 - 1.77，P=0.121）。Nanog高表达与NSCLC患者的不良预后相关，且Nanog可能作为NSCLC的预后预测指标。
